Panic & Anxiety Gone Offers 75% Commission.

Panic & Anxiety Gone Is A Site Retailing Advice For People Suffering From Panic Attacks And Chronic Anxiety, And Every Sale Offers You A Whopping 75% Commission! Extensive Affiliate Resource Area At Http://www.panicanxietygone.com/affiliates/.

Panic & Anxiety Gone Offers 75% Commission.

Filed under Leukaemia, chronic myeloid | Comment (0)

Heal Chronic Illness.

Heal Chronic Illness Is My Experience And Embraces A Comprehensive Yet Uncomplicated Approach To Healing Chronic Illness Sensibly, Responsibly, Gently, Resulting In Long Lasting, If Not Permanent Relief Of Pain And Symptoms.

Heal Chronic Illness.

Filed under Leukaemia, chronic myeloid | Comment (0)

Chronic Fatigue Syndrome.

What Doctors Don’t Tell You Because They Don’t Know. In My Course I Provide You With Hard Earned, Practical Knowledge For Successfully Overcoming Chronic Fatigue Syndrome Using Natural Medicine.

Chronic Fatigue Syndrome.

Filed under Leukaemia, chronic myeloid | Comment (0)

A Healthy Back In Ten Minutes A Day.

Safe, Simple And Effective Exercises You Can Do Anywhere To Help Relieve That Back Pain And Put An End To That Chronically Sore Back. No Gyms Or Special Equipment Needed.

A Healthy Back In Ten Minutes A Day.

Filed under Leukaemia, chronic myeloid | Comment (0)

Complete Information on Essential Thrombocytopenia

Essential thrombocytopenia is a rare blood disease characterized by the reduced levels of the plates in the blood of circulation. The essential thrombocythemia is one of the diseases myeloproliferative. MPDs also include will vera it polycythemia (statement), the metaplasia myéloïde of Agnogenic , the secondary myelofibrosis and chronic leukaemia myelogenous. AND can occur at any age but tends to being more common in the adults. Essential thrombocytopenia assigns women and men. The symptoms of essential thrombocytopenia include the headache, burning or tinkling in the hands or the feet, redness and heat of the hands.

Essential thrombocytosis can be dependent with the greatest risk of abortion or loss spontaeous in the first quarter of the pregnancy. The treatment of essential thrombocytopenia depends on the level of the plates in blood and the risk of coagulation or to bleed of the complications. Medicines can help to limit the risk of bleeding and complications of coagulation. Aspirin is largely widespread inside ET, in particular for symptoms probably to be due to coagulation or the too active plates. Aspirin of low-amount is largely widespread to reduce the risk of thrombosis, but there can is a greater risk of bleeding.

Hydroxycarbamide functions beside the interference the metabolism of the cell. It is a common treatment for essential thrombocytopenia and usually the needs to be taken daily. The phosphorus of Melphalan, busulfan and radioactive belong to medicines of a group called the agents of alkylation and employed to be the principal treatment for DNA. They reduce the account of cells while binding to DNA and by damaging it, preventing the complete separation of two banks of DNA to the division of cells. Anagrelide lowers the account of plate specifically. It seems to function beside reducing the size of the plate-producing cells in marrow.

Filed under Leukaemia, chronic myeloid | Comment (0)

Cancer Research, Why Haven’t They Found a Better Treatment?

War was declared on cancer in 1971 and since then billions of dollars have been spent looking for a cure for the disease. Research has concentrated on finding a drug or a better way to treat cancer but so far anything they have come up with has only been marginally better than current treatments. Why haven’t they made progress when all other areas of medical science have made huge advancements? The reason is very simple. Cancer is similar to the diseases Scurvy, Beriberi, Pellagra and Pernicious Anaemia and those diseases are deficiency diseases, in other words the body is deficient in a certain vitamin or mineral and the only way to overcome those diseases is to eat the foods that contain the missing nutrients that the body is lacking in. Cancer is exactly the same, cancer will take hold when our immunity is down because of our modern way of living with our high consumption of processed foods, the wrong foods we eat, the toxic chemicals we are in contact with daily and our sedentary lifestyle.
Research over the last 30 to 40 years has concentrated on finding a drug or an artificial substance to patent as the potential as a money earner is enormous.
Even the latest drugs which are Gleevic for CML (Chronic Myeloid Leukaemia) and Herceptin for a type of breast cancer are only marginally better than other chemotherapy agents that were used in the past. Even then a course of Gleevic was costing $60,000 and for Herceptin, it was even higher.
Nothing, except money is to be gained by pretending that the battle against cancer is slowly but surely being won.

Fortunately public funded research like university’s are now starting to look at our natural foods and are discovering many cancer fighting properties within those foods. Many of these compounds which are called phytochemicals or phytonutrients have been found to have amazing cancer fighting properties. They are finding that most of our basic food items are found to have many benefits to a cancer patient. These are not only in preventing cancer but stopping cancer once it’s established. Our natural food in its fresh form has absolutely no side effects and the cancer fighting properties found to be beneficial to a cancer patient are many and varied.
A few examples that research has found are;

* Cruciferous vegetables in which broccoli is one of them. They may be bland and boring but when it comes to fighting cancer they are unequal.
* Onion family which includes garlic in which research has found to be extremely beneficial. It is well known that in places where garlic consumption is high, cancer incident is low.
* Tomatoes reduces the risk of prostrate and breast cancer.
* Carrots, red capsicum and dark green vegetables, all stimulate the immune system.
* Spinach, beans, peas and other pulses, inhibits all cancers.

* Berries, grapes and citrus fruits have also been found to be beneficial to a cancer patient.

Remember that there is no drug, no surgical procedure or no high technical procedure that comes even close to the astonishing healing power of our natural food.
A true cure for cancer will only be achieved when a patient stimulates their own body’s defense system and there are only natural ways to do that. That is why they haven’t found a cure for cancer.

Filed under Leukaemia, chronic myeloid | Comment (0)

Launching Next Generation Oncology Products: Evolving Strategies in a Payors Market–Aarkstore Enterprise

Aarkstore announce a new report  ” Launching Next Generation Oncology Products: Evolving Strategies in a Payors Market ” through its vast collection of market research report.

The emergence of a new wave of oncology products has been one of the most dramatic trends in the pharmaceutical market over the last decade. Both large and small companies are making unprecedented investments in oncology R&D, in an effort to emulate the success of new targeted therapies such as Herceptin, Avastin, Glivec, Nexavar and Erbitux.

Underpinning that success have been real improvements in therapeutic options for a range of cancers, including marked survival increments in areas of poor prognosis, such as kidney cancer (e.g., Sutent); more effective therapies, tailored to genetically defined subgroups, for widespread malignancies (Herceptin for breast cancer); and innovations that have transformed fatal into chronic diseases (Glivec for chronic myeloid leukaemia).

At the same time, success has come at a price. Not is the oncology marketplace getting more crowded, raising the bar for differentiation in a category in which many products are focusing on the same disease mechanisms, but the premium prices charged for newer therapies are stretching healthcare budgets. Increasingly cancer drugs are losing the special status that once guaranteed uptake at any cost and are coming under the same cost-effectiveness scrutiny as other components of healthcare.

In today’s payer’s market, oncology companies are being forced to re-assess their strategies and build a compelling value equation for their products that will meet the needs of a whole range of stakeholders, each with their own agenda. And they must do this while finding a way to recoup R&D costs from niche products without the patient volumes that have driven blockbuster brands in the past.

Key findings

Worldwide sales of cancer drugs are forecast to increase at a compound annual growth rate of 12-15% from 2008, reaching US$75-80 billion by 2012. That would represent almost double the projected growth rate for the pharmaceutical market as a whole over the same period.

At the same time, growth of the category is expected to slow over the next five years, with a diminishing contribution from the existing top oncology markets – the US, France, Germany, Italy, the UK and Spain. These countries accounted for 71% of oncology product sales worldwide in 2007. By 2012, however, their share of overall sales could be down to 65%.

Increased cost-sensitivity among payers, market crowding and the loss of cancer’s ‘special status’ will make the market much for challenging for established oncology players and new contenders over the next few years.

Key features of this report

Detailed analysis of the new forces driving growth in the worldwide oncology market.

Overview of the cost pressures on healthcare systems and growing recourse to health technology assessment that are complicating market entry for new cancer drugs.

Analysis of NICE decisions on premium-priced oncology products, the wider political context in which these decisions are taken, and what they could mean for oncology players in other markets.

Detailed exploration of how a multi-faceted value proposition needs to be constructed for new cancer therapies, including survival benefits, cost-effectiveness and more personal components such as quality of life.

Use this report to

Detailed understanding of the new growth drivers in the world oncology market and the emerging threats to continued growth

Insight into how healthcare systems are evolving in their efforts to manage cost inflation and how these changes present significant challenges to oncology market growth.

Compare approaches to health technology assessment in key markets such as the UK and the US; understand how these raise the bar to entry for new oncology products.

Detailed insight into the different components of value that will enable new cancer therapies to carve out niches in the new payer-dominated environment.

Discover

What will be the market trend for oncology products in the years to 2012 and beyond?

How has the treatment paradigm for oncology changed in terms of targeted therapies, niche indications and payer influence?

What are governments, HTA agencies, health insurers and other influencers/payers in key markets such as the UK and the US doing to address budgetary pressure from pharmaceuticals in general and new oncology products in particular?

For more information, please visit :
http://www.aarkstore.com/reports/Launching-Next-Generation-Oncology-Products-Evolving-Strategies-in-a-Payors-Market-34832.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Filed under Leukaemia, chronic myeloid | Comment (0)